Becić Fahir, Kapić Elvedina, Becić Ervina
Institut za farmakologiju, Klinicku Farmakologiju i toksikologiju, Medicinski fakultet Univerziteta u Sarajevu.
Med Arh. 2003;57(2):125-7.
Glimepiride is the oral antidiabetic, second-generation sulfonylurea. It is structurally similar to glyburide. Glimepiride exhibited more potent glucose-lowering effects than glyburide and longer duration of hypoglycemic effect. Glimepiride is useful in the treatment of non-insulin-dependent (type II) diabetes mellitus. Glimepiride is indicated as an adjunct to diet and exercise for non-insulin dependent diabetes mellitus. Glimepiride reduces glucose levels blood by stimulating insulin release from functional pancreatic beta cells in response to glucose. Glimepiride in daily dose 1 to 8 mg is causing a dose-related decrease blood glucose levels and glycosylated hemoglobin fasting state and postprandially. If the maximum dose of glimepiride fails to lower blood glucose sufficiently, metformine or insuline may be added to glimepiride monotherapy. Glimepiride is very safe drug and adverse effects causing by glimepiride are very rare. The risk of hypoglycemia after use of glimepiride is very small, therefore is the therapy with glimepiride is more preferable than the therapy with glibenclamide.
格列美脲是一种口服抗糖尿病药物，属于第二代磺酰脲类。它在结构上与格列本脲相似。格列美脲的降糖作用比格列本脲更强，且低血糖作用持续时间更长。格列美脲可用于治疗非胰岛素依赖型（II型）糖尿病。格列美脲被指定为非胰岛素依赖型糖尿病饮食和运动治疗的辅助药物。格列美脲通过刺激功能性胰腺β细胞对葡萄糖作出反应来释放胰岛素，从而降低血糖水平。每日剂量为1至8毫克的格列美脲会导致空腹和餐后血糖水平及糖化血红蛋白呈剂量相关下降。如果格列美脲的最大剂量不能充分降低血糖，可在格列美脲单药治疗中加用二甲双胍或胰岛素。格列美脲是一种非常安全的药物，由格列美脲引起的不良反应非常罕见。使用格列美脲后发生低血糖的风险非常小，因此格列美脲治疗比格列本脲治疗更可取。
